Hennion & Walsh Asset Management, Inc. 89bio, Inc. Transaction History
Hennion & Walsh Asset Management, Inc.
- $2.35 Billion
- Q2 2025
A detailed history of Hennion & Walsh Asset Management, Inc. transactions in 89bio, Inc. stock. As of the latest transaction made, Hennion & Walsh Asset Management, Inc. holds 211,955 shares of ETNB stock, worth $1.94 Million. This represents 0.09% of its overall portfolio holdings.
Number of Shares
211,955
Previous 140,306
51.07%
Holding current value
$1.94 Million
Previous $1.13 Million
83.67%
% of portfolio
0.09%
Previous 0.05%
Shares
3 transactions
Others Institutions Holding ETNB
# of Institutions
211Shares Held
161MCall Options Held
366KPut Options Held
944K-
Janus Henderson Group PLC London, X020.5MShares$187 Million0.09% of portfolio
-
Ra Capital Management, L.P. Boston, MA19.9MShares$182 Million3.0% of portfolio
-
Suvretta Capital Management, LLC New York, NY14.3MShares$131 Million4.56% of portfolio
-
Deep Track Capital, LP Greenwich, CT9.32MShares$85.2 Million2.37% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.16MShares$65.5 Million0.0% of portfolio
About 89bio, Inc.
- Ticker ETNB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 46,484,500
- Market Cap $425M
- Description
- 89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...